Literature DB >> 20457267

Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients.

Shun-Ichi Kimura1, Kumi Oshima, Ken Sato, Miki Sato, Kiriko Terasako, Hideki Nakasone, Misato Kikuchi, Shinya Okuda, Shinichi Kako, Rie Yamazaki, Yukie Tanaka, Aki Tanihara, Junji Nishida, Yoshinobu Kanda.   

Abstract

We investigated the impact of neutropenia on the development of early bloodstream and pulmonary infections in hematopoietic stem cell transplantation (HSCT) recipients, and evaluated the utility of an index (D-index) that reflects both the intensity and duration of neutropenia. Fifty-eight patients (23 autologous, 35 allogeneic HSCT recipients) were enrolled in this retrospective study. The D-index was defined as the area over the neutrophil curve during neutropenia. We also evaluated the utility of the cumulative D-index from the start of neutropenia until the development of infection (c-D-index), which may enable real-time assessment of the risk for infection. The patients showed 12 and 7 episodes of bloodstream and pulmonary infection, respectively. The D-index, days of neutropenia (<500/microL) and days of profound neutropenia (<100/microL) had at least a nearly significant impact on the development of both bloodstream and pulmonary infections. On the other hand, the c-D-index, cumulative days of neutropenia, and cumulative days of profound neutropenia significantly affected pulmonary infection, but not bloodstream infection. The c-D-index had a high negative predictive value of 97.4% for pulmonary infection with a cutoff of 5500, but the area under the receiver operating characteristic curve was similar to that of the cumulative days of neutropenia and profound neutropenia. Our results showed that although the c-D-index may be useful for identifying patients who are at low risk for early pulmonary infection after HSCT, its performance was similar to that of the simple duration of neutropenia.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457267     DOI: 10.1016/j.bbmt.2010.04.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases.

Authors:  S-I Kimura; T Murata; Y Akahoshi; H Nakano; T Ugai; H Wada; R Yamasaki; Y Ishihara; K Kawamura; K Sakamoto; M Ashizawa; M Sato; K Terasako-Saito; H Nakasone; M Kikuchi; R Yamazaki; S Kako; J Kanda; A Tanihara; J Nishida; Y Kanda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-11       Impact factor: 3.267

2.  The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients.

Authors:  Cybele Lara R Abad; Brian Lahr; John C O'Horo; Prakhar Vijayvargiya; Randall C Walker; William J Hogan; Aaron J Tande
Journal:  Int J Hematol       Date:  2019-11-11       Impact factor: 2.490

3.  The predictive value for pulmonary infection by area over the neutrophil curve (D-index) in patients who underwent reduced intensity hematopoietic stem cell transplantation.

Authors:  Jun Aoki; Masaharu Tsubokura; Kazuhiko Kakihana; Gaku Oshikawa; Takeshi Kobayashi; Noriko Doki; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Pathol Oncol Res       Date:  2014-04-05       Impact factor: 3.201

4.  Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>.

Authors:  Jason N Barreto; Kristen B McCullough; Candy S Peskey; Ross A Dierkhising; Kristin C Mara; Michelle A Elliott; Dennis A Gastineau; Aref Al-Kali; Naseema Gangat; Louis Letendre; William J Hogan; Mark R Litzow; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2017-05-09

5.  Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Authors:  Yasufumi Kawasaki; Shun-Ichi Kimura; Hirofumi Nakano; Kiyomi Mashima; Yuya Shirato; Shin-Ichiro Kawaguchi; Yumiko Toda; Shin-Ichi Ochi; Takashi Nagayama; Daisuke Minakata; Ryoko Yamasaki; Kaoru Morita; Masahiro Ashizawa; Chihiro Yamamoto; Kaoru Hatano; Kazuya Sato; Iekuni Oh; Shin-Ichiro Fujiwara; Ken Ohmine; Shinichi Kako; Kazuo Muroi; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2019-01-25       Impact factor: 2.490

6.  The use of intravenous antibiotics at the onset of neutropenia in patients receiving outpatient-based hematopoietic stem cell transplants.

Authors:  Aziz Hamadah; Yoko Schreiber; Baldwin Toye; Sheryl McDiarmid; Lothar Huebsch; Christopher Bredeson; Jason Tay
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

7.  D-index as a marker of bloodstream infections in patients with allogeneic hematopoietic stem cell transplantation.

Authors:  Prakhar Vijayvargiya; Cybele Lara Abad; Zerelda Esquer Garrigos; John C O'Horo; Randall C Walker; William J Hogan; Aaron J Tande
Journal:  Transpl Infect Dis       Date:  2021-03-01

8.  D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections.

Authors:  Gülden Yılmaz; Belgin Coşkun; Atilla Elhan; Alpay Azap; Hamdi Akan
Journal:  Turk J Haematol       Date:  2014-05-21       Impact factor: 1.831

9.  c-D-index at day 11 can predict febrile neutropenia during chemotherapy in acute myeloid leukemia.

Authors:  Hiroyuki Kubo; Osamu Imataki; Yukiko Hamasaki Kubo; Makiko Uemura
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

10.  Serial platelet level index improves prediction of pulmonary hemorrhage in patients with Stenotrophomonas maltophilia respiratory infections and thrombocytopenia.

Authors:  Huai-Chueh Gem Wu; Huai-Shing Wu; Chao-Neng Cheng; Jiann-Shiuh Chen; Tsai-Yun Chen; Chung-I Li; Ching-Fen Shen
Journal:  Front Med (Lausanne)       Date:  2022-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.